Long term outcomes primarily depend on left ventricular function
Primary mitral valve disease involves damage to leaflet or chordal tissue,1 whereas functional (or secondary) mitral regurgitation (MR) typically involves a combination of mitral annular dilatation and leaflet restriction caused by ventricular dysfunction in patients with normal leaflets and chordae. Assessing the severity of regurgitation in secondary MR is more difficult than in primary MR, as the regurgitant orifice area is often underestimated by echocardiography because of its crescent shape during systole. Left ventricular stroke volume is usually reduced in secondary MR, so that lesser degrees of regurgitant volume are more significant.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Nishimura RA, Otto CM, Bonow RO, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practical Guidelines. Circulation 2014; 129: 2440-2492.
- 2. Levine RA, Hung J, Otsuji Y, et al. Mechanistic insights into functional mitral regurgitation. Curr Cardiol Rep 2002; 4: 125-299.
- 3. van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. Circulation 2011; 124: 912-919.
- 4. Sand ME, Naftel DC, Blackstone EH, et al. A comparison of repair and replacement for mitral valve incompetence. J Thorac Cardiovasc Surg 1987; 94: 208-219.
- 5. Lee SJ, Bay KS. Mortality risk factors associated with mitral valve replacement: a survival analysis of 10 year follow-up data. Can J Cardiol 1991; 7: 11-18.
- 6. The Australian and New Zealand Society of Cardiac and Thoracic Surgeons. National Cardiac Surgery Database Program: national annual report 2013. https://anzscts.org/wp-content/uploads/2015/06/Database-National-Annual-Report-2013.pdf (accessed July 2016).
- 7. Rama A, Nappi F, Praschker BG, Gandjbakhch I. Papillary muscle approximation for ischemic mitral valve regurgitation. J Card Surg 2008; 23: 733-735.
- 8. Hvass U, Tapia M, Baron F, et al. Papillary muscle sling: a new functional approach to mitral repair in patients with ischemic left ventricular dysfunction and functional mitral regurgitation. Ann Thorac Surg 2003; 75: 809-811.
- 9. Kincaid EH, Riley RD, Hines MH, et al. Anterior leaflet augmentation for ischemic mitral regurgitation. Ann Thorac Surg 2004; 78: 564-568.
- 10. Alfieri O, De Bonis M, Lapenna E, et al. “Edge-to-edge” repair for anterior mitral leaflet prolapse. Semin Thorac Cardiovasc Surg 2004; 16: 182-187.
- 11. De Bonis M, Lapenna E, La Canna G, et al. Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy. role of the “edge-to-edge” technique. Circulation 2005; 112 (9 Suppl): I402-I408.
- 12. Brinster DR, Unic D, D'Ambra MN, et al. Midterm results of the edge-to-edge technique for complex mitral valve repair. Ann Thorac Surg 2006; 811: 612-617.
- 13. Michler RE, Smith PK, Parides MK, et al; Cardiothoracic Surgical Trials Network. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016; 374: 1932-1941.
- 14. Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc Surg 1995; 109: 676-682.
- 15. Nickenig G, Estevez-Loureiro R, Franzen O, et al; Transcatheter Valve Treatment Sentinel Registry Investigators of the EURObservational Research Programme of the European Society of Cardiology. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011–2012 Pilot European Sentinel Registry. J Am Coll Cardiol 2014; 64: 875-884.
No relevant disclosures.